DaVita (NYSE:DVA) Stock Bumped Down to Hold by Wall Street Zen

Key Points

• Wall Street Zen downgraded DaVita from “Buy” to “Hold,” joining other analysts in a cautious outlook. The stock has an average rating of “Hold” and an average price target of $233.43.
• DaVita reported quarterly EPS of $4.02, exceeding the $3.88 analyst consensus, while revenue rose 5.2% year over year to $3.55 billion. The company guided to fiscal 2026 EPS of $14.10–$15.20.
• Institutional ownership remains high at 90.12%, with Berkshire Hathaway acquiring a roughly $6.43 billion stake and BlackRock purchasing approximately $547.5 million of shares during the second quarter.

DaVita (NYSE:DVA - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other equities analysts also recently commented on the stock. Raymond James Financial set a $220.00 target price on shares of DaVita in a research note on Friday, August 7th. Truist Financial dropped their price objective on DaVita from $250.00 to $215.00 and set a "hold" rating on the stock in a report on Friday, August 7th. Weiss Ratings lowered DaVita from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday. Oppenheimer set a $220.00 price target on DaVita in a report on Friday, August 7th. Finally, Barclays increased their price target on shares of DaVita from $218.00 to $224.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $233.43.

DaVita Stock Up 2.1%

Shares of DVA stock opened at $178.29 on Friday. The firm has a 50 day moving average of $194.23 and a two-hundred day moving average of $187.67. The stock has a market capitalization of $11.38 billion, a PE ratio of 14.59, a P/E/G ratio of 0.45 and a beta of 0.83. DaVita has a 52 week low of $101.00 and a 52 week high of $247.49.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. During the same period last year, the business posted $2.95 earnings per share. DaVita's revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Analysts expect that DaVita will post 14.57 EPS for the current fiscal year.

Institutional Trading of DaVita

Institutional investors and hedge funds have recently bought and sold shares of the business. Berkshire Hathaway Inc acquired a new stake in DaVita in the second quarter valued at about $6,425,269,000. BlackRock Inc. acquired a new position in DaVita during the 2nd quarter worth approximately $547,520,000. Bank of America Corp DE purchased a new position in shares of DaVita during the 2nd quarter worth approximately $145,057,000. Arrowstreet Capital Limited Partnership lifted its holdings in shares of DaVita by 114.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company's stock valued at $135,196,000 after buying an additional 636,191 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in shares of DaVita in the second quarter valued at approximately $101,127,000. Hedge funds and other institutional investors own 90.12% of the company's stock.

DaVita Company Profile

DaVita Inc NYSE: DVA is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.

DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.